JP2018095632A - Tablet containing the esomeprazole salt having improved chemical stability - Google Patents

Tablet containing the esomeprazole salt having improved chemical stability Download PDF

Info

Publication number
JP2018095632A
JP2018095632A JP2017073369A JP2017073369A JP2018095632A JP 2018095632 A JP2018095632 A JP 2018095632A JP 2017073369 A JP2017073369 A JP 2017073369A JP 2017073369 A JP2017073369 A JP 2017073369A JP 2018095632 A JP2018095632 A JP 2018095632A
Authority
JP
Japan
Prior art keywords
tablet
weight
uncoated tablet
additive
esomeprazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017073369A
Other languages
Japanese (ja)
Other versions
JP6336651B1 (en
Inventor
俊哉 谷口
Toshiya Taniguchi
俊哉 谷口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ohara Pharmaceutical Co Ltd
Original Assignee
Ohara Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ohara Pharmaceutical Co Ltd filed Critical Ohara Pharmaceutical Co Ltd
Priority to PCT/JP2017/045018 priority Critical patent/WO2018110683A1/en
Application granted granted Critical
Publication of JP6336651B1 publication Critical patent/JP6336651B1/en
Publication of JP2018095632A publication Critical patent/JP2018095632A/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

PROBLEM TO BE SOLVED: To provide technical means (desirably simple one) for producing a tablet in which the chemical stability of the salt of esomeprazole is improved.SOLUTION: The present invention provides an uncoated tablet having suppressed absorbency in which the metal salt of esomeprazole, and an additive with low absorbency are contained in an amount of 80.0% by weight or more with respect to the total weight of an uncoated tablet, and in which preferably, the additive comprises one or two excipients, one or two disintegrants, one or two binders, and one or two lubricants. The additive with low absorbency includes lactose hydrate, anhydrous lactose, D-mannitol, xylitol, D-sorbitol, maltitol, maltose, sucrose, and powder reduced maltose syrup.SELECTED DRAWING: None

Description

本発明は、原薬としてエソメプラゾール又は其の塩（特にエソメプラゾールマグネシウム水和物）を含有する製剤に関するものであり、其の保存条件下における原薬の化学的な安定性を改善するための詳細な方法を開示するものである。   The present invention relates to a preparation containing esomeprazole or a salt thereof (especially esomeprazole magnesium hydrate) as a drug substance, and improves the chemical stability of the drug substance under its storage conditions. A detailed method is disclosed.

エソメプラゾール（一般名）は、ラセミ体であるオメプラゾールに含まれる光学異性体（Ｓ体）であり、薬理作用として胃酸分泌抑制作用等を有する薬剤である。エソメプラゾールは、胃潰瘍、十二指腸潰瘍、吻合部潰瘍、ゾリンジャー−エリソン症候群、逆流性食道炎、非びらん性胃食道逆流症、非ステロイド性抗炎症薬投与時における胃潰瘍又は十二指腸潰瘍の再発抑制、低用量アスピリン投与時における胃潰瘍、及び十二指腸潰瘍の再発抑制等の治療に有用である（非特許文献１等参考）。   Esomeprazole (generic name) is an optical isomer (S form) contained in racemic omeprazole, and has a gastric acid secretion inhibitory action as a pharmacological action. Esomeprazole is a gastric ulcer, duodenal ulcer, anastomotic ulcer, Zollinger-Ellison syndrome, reflux esophagitis, non-erosive gastroesophageal reflux disease, suppression of recurrence of gastric ulcer or duodenal ulcer during nonsteroidal anti-inflammatory drug administration, low It is useful for the treatment of gastric ulcer and duodenal ulcer recurrence suppression at the time of administration of a dose aspirin (see Non-Patent Document 1, etc.).

現在、エソメプラゾールマグネシウム水和物はカプセル剤の剤形で医療現場に提供されている。オメプラゾール乃至はエソメプラゾールを含有する製剤の処方や製造方法は、以下の特許文献１〜４等で紹介されている。特許文献１、２の実施例ではオメプラゾールマグネシウムを含む腸溶性コーティングされた組成物を含有する錠剤等が記載され、特許文献３の実施例ではオメプラゾールを含むコアに分離層、次いで腸溶コーティング層を被覆した組成物が記載される。オメプラゾールは酸性・中性の環境下で分解されやすく、アルカリ性の物質と混合することで化学的に安定化しやすいことが特許文献１等に記載されている。   Currently, esomeprazole magnesium hydrate is provided to the medical field in capsule dosage form. The prescription and manufacturing method of the preparation containing omeprazole or esomeprazole are introduced in the following Patent Documents 1 to 4 and the like. In Examples of Patent Documents 1 and 2, tablets containing an enteric-coated composition containing omeprazole magnesium are described, and in Example of Patent Document 3, a separation layer and then an enteric coating layer are formed on a core containing omeprazole. The coated composition is described. Patent Document 1 describes that omeprazole is easily decomposed in an acidic / neutral environment and is easily chemically stabilized by mixing with an alkaline substance.

固形製剤の剤形として最も一般的なものは錠剤であり、錠剤はフィルムコーティング錠とされる場合が多い。剤形を錠剤とすることには、調剤の際の計数の容易さや大量生産が可能等のメリットがあるが、更にフィルムコーティング錠とすることで遮光性、腸溶性及び印字性等の特性（特に印字性）を好ましいものにすることも可能である。但し、エソメプラゾールマグネシウム水和物については剤形が錠剤である場合の先行文献による技術的な示唆（特に化学的な安定性を改善する方法や工業的に簡便に製造する方法）は乏しく、本願発明者は優れたエソメプラゾールマグネシウム水和物を含有するフィルムコーティング錠を工業的に簡便に製造するために其の処方や製造方法について鋭意検討を重ねる必要があった。   The most common solid dosage form is a tablet, and the tablet is often a film-coated tablet. Making the dosage form a tablet has advantages such as ease of counting at the time of dispensing and mass production, etc., but by making it a film-coated tablet, characteristics such as light shielding properties, enteric properties and printability (especially It is also possible to make the printability favorable. However, for esomeprazole magnesium hydrate, there is little technical suggestion (especially a method for improving chemical stability or a method for industrially simple production) when the dosage form is a tablet, The inventor of the present application had to intensively study the formulation and the production method in order to industrially easily produce a film-coated tablet containing excellent esomeprazole magnesium hydrate.

特許第３３５００５４号公報Japanese Patent No. 3350054 特許第５４１２０２１号公報Japanese Patent No. 5412021 特許第４６４９００１号公報Japanese Patent No. 4646901 特許第４６１００８６号公報Japanese Patent No. 4610086

「ネキシウム（登録商標）カプセル１０ｍｇ２０ｍｇ」医薬品インタビューフォーム ２０１６年２月改訂（改訂第１０版）"Nexium (registered trademark) capsule 10mg 20mg" Drug Interview Form Revised February 2016 (10th revised edition)

本発明は、エソメプラゾールの塩（特にエソメプラゾールマグネシウム水和物）の化学的な安定性等が改善された錠剤（好ましくはフィルムコーティング錠）を製造するための技術的手段（望ましくは簡便なもの）を提供することを目的とするものである。   The present invention provides a technical means (preferably simple and convenient) for producing a tablet (preferably a film-coated tablet) having improved chemical stability or the like of a salt of esomeprazole (especially esomeprazole magnesium hydrate). Is intended to provide

本発明者は、上記の課題を解決するべく鋭意検討した結果、エソメプラゾールマグネシウム水和物を含有する素錠の水分の吸湿量が抑制されるようにした上で、簡易な構成の処方並びに方法で製造した場合に、化学的安定性が顕著に優れていることを見出した。その場合には意外にも、塩基性の安定化剤は不要であることが示唆された。本発明者はその知見に基づいて更に鋭意検討を重ね、下記の本発明を完成するに至った。   As a result of intensive studies to solve the above-mentioned problems, the present inventor tried to suppress the moisture absorption amount of the uncoated tablets containing esomeprazole magnesium hydrate, and to formulate a simple structure and It was found that the chemical stability was remarkably excellent when produced by the method. In that case, it was unexpectedly suggested that a basic stabilizer is unnecessary. The inventor has conducted further intensive studies based on the findings, and has completed the present invention described below.

本発明は、吸湿量を抑制したエソメプラゾールの塩を含有する錠剤又は其の製造方法に関するものであり、その好ましい構成は以下（１）〜（１３）において記述されるものである。
（１）エソメプラゾールの金属塩並びに吸湿性が低い添加剤が素錠の全重量に対して７０．０重量％以上含有され、好ましくは吸湿性が高い添加剤が素錠の全重量に対して１５．０重量％以上含有されず、好ましくは乾燥減量値が１．８重量％以下であり、好ましくは素錠中に含まれる添加剤が１〜２種類の賦形剤、１〜２種類の崩壊剤、１〜２種類の結合剤及び１〜２種類の滑沢剤からなる、吸湿量が抑制された素錠。
（２）エソメプラゾールの金属塩がエソメプラゾールマグネシウム水和物であり、好ましくは吸湿性が高い添加剤が素錠の全重量に対して１０．０重量％以上含有されず、好ましくは乾燥減量値が１．０重量％以下であり、好ましくは素錠中に含まれる添加剤が１種類の賦形剤、１種類の崩壊剤、１種類の結合剤及び１種類の滑沢剤からなる、前記（１）に記載の素錠。
（３）吸湿性が低い添加剤が、温度２５度相対湿度７５％の条件下において３．０％未満の平衡含水率（％（ｗ／ｗ））を示すものであり、吸湿性が高い添加剤が、温度２５度相対湿度７５％の条件下において１５．０％以上の平衡含水率（％（ｗ／ｗ））を示すものである、前記（１）又は（２）に記載の素錠。
（４）吸湿性が低い添加剤が水和物ではない、前記（１）〜（３）のいずれかに記載の素錠。
（５）エソメプラゾールの金属塩を素錠の全重量に対して６．０〜５０．０重量％含有する、前記（１）〜（４）のいずれかに記載の素錠。
（６）吸湿性が低い賦形剤を含み、前記の賦形剤がＤ-マンニトール、キシリトール、白糖、スクロース及びトレハロースから選択されるものである、前記（１）〜（５）のいずれかに記載の素錠。
（７）吸湿性が低い賦形剤を含み、前記の賦形剤が素錠の全重量に対して５０．０重量％以上含有される、前記（１）〜（６）のいずれかに記載の素錠。
（８）エソメプラゾールの金属塩を含む造粒物を含有する、前記（１）〜（７）のいずれかに記載の素錠。
（９）吸湿性が高い添加剤が素錠の全重量に対して６．０重量％以上含有されない、前記（１）〜（８）のいずれかに記載の素錠。
（１０）吸湿性が高い添加剤がトウモロコシデンプン、バレイショデンプン、コムギデンプン、コメデンプン、デンプングリコール酸ナトリウム、ポビドン、クロスポビドン、カルメロース、カルメロースカルシウム、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ及びクロスカルメロースナトリウムから選択されるものであり、好ましくは崩壊剤である、前記（１）〜（９）のいずれかに記載の素錠。
（１１）塩基性の添加剤を含有しない、前記（１）〜（１０）のいずれかに記載の素錠。
（１２）前記（１）〜（１１）のいずれかに記載の素錠がフィルムコーティング層（望ましくは腸溶性高分子を含む。）で覆われた錠剤。
（１３）エソメプラゾールの金属塩、１〜２種類の賦形剤、及び１〜２種類の崩壊剤を混合し、次いで其の混合物に１〜２種類の結合剤を含む造粒液を噴霧・乾燥して造粒物を製造し、続いて其の造粒物を１〜２種類の滑沢剤と混合した後に圧縮成形する、前記（１）〜（１２）のいずれかに記載の素錠を製造する方法。 The present invention relates to a tablet containing a salt of esomeprazole with reduced moisture absorption or a method for producing the same, and preferred configurations thereof are described in (1) to (13) below.
(1) The metal salt of esomeprazole and the additive having low hygroscopicity are contained in an amount of 70.0% by weight or more based on the total weight of the uncoated tablet, preferably the additive having high hygroscopic property is based on the total weight of the uncoated tablet. 15.0% by weight or more, preferably a loss on drying value of 1.8% by weight or less, preferably 1 to 2 types of excipients, 1 to 2 types of additives contained in uncoated tablets An uncoated tablet with reduced moisture absorption, comprising 1 disintegrant, 1 to 2 types of binder and 1 to 2 types of lubricant.
(2) The metal salt of esomeprazole is esomeprazole magnesium hydrate, and preferably no highly hygroscopic additive is contained in an amount of 10.0% by weight or more based on the total weight of the uncoated tablet, preferably dried. The weight loss value is 1.0% by weight or less. Preferably, the additive contained in the uncoated tablet consists of one type of excipient, one type of disintegrant, one type of binder and one type of lubricant. The uncoated tablet according to (1) above.
(3) An additive having a low hygroscopic property exhibits an equilibrium water content (% (w / w)) of less than 3.0% under the condition of a temperature of 25 ° C. and a relative humidity of 75%. The uncoated tablet according to (1) or (2), wherein the agent exhibits an equilibrium water content (% (w / w)) of 15.0% or more under the condition of a temperature of 25 degrees and a relative humidity of 75% .
(4) The uncoated tablet according to any one of (1) to (3), wherein the additive having low hygroscopicity is not a hydrate.
(5) The plain tablet according to any one of (1) to (4) above, containing 6.0 to 50.0% by weight of a metal salt of esomeprazole based on the total weight of the plain tablet.
(6) In any one of the above (1) to (5), including an excipient with low hygroscopicity, wherein the excipient is selected from D-mannitol, xylitol, sucrose, sucrose and trehalose The uncoated tablet described.
(7) The composition according to any one of (1) to (6), including an excipient having low hygroscopicity, wherein the excipient is contained in an amount of 50.0% by weight or more based on the total weight of the uncoated tablet. Uncoated tablet.
(8) The plain tablet in any one of said (1)-(7) containing the granulated material containing the metal salt of esomeprazole.
(9) The plain tablet according to any one of (1) to (8), wherein an additive having high hygroscopicity is not contained in an amount of 6.0% by weight or more based on the total weight of the plain tablet.
(10) Additives with high hygroscopicity include corn starch, potato starch, wheat starch, rice starch, sodium starch glycolate, povidone, crospovidone, carmellose, carmellose calcium, low-substituted hydroxypropylcellulose, hydroxypropyl starch and cloth The uncoated tablet according to any one of (1) to (9), which is selected from carmellose sodium, and preferably a disintegrant.
(11) The uncoated tablet according to any one of (1) to (10), which does not contain a basic additive.
(12) A tablet in which the uncoated tablet according to any one of (1) to (11) is covered with a film coating layer (preferably containing an enteric polymer).
(13) A metal salt of esomeprazole, 1 to 2 types of excipients, and 1 to 2 types of disintegrant are mixed, and then the mixture is sprayed with a granulating liquid containing 1 to 2 types of binders. -The raw material according to any one of the above (1) to (12), which is dried to produce a granulated product, which is then compression-molded after mixing the granulated product with one or two kinds of lubricants. A method of manufacturing a tablet.

本発明により、化学的な安定性等が改善されたエソメプラゾールの塩（特にエソメプラゾールマグネシウム水和物）を含有する素錠並びにフィルムコーティング錠を製造（望ましくは工業的に簡便な方法で）することが可能となる。   According to the present invention, uncoated tablets and film-coated tablets containing salts of esomeprazole (especially esomeprazole magnesium hydrate) with improved chemical stability and the like are manufactured (preferably by an industrially simple method). ).

以下で本発明の、吸湿量を抑制したエソメプラゾールの塩を含有する錠剤の処方及び其の製造方法を詳細に説明する。但し、以下の記載は本発明を説明するための例示であり、本発明の技術的範囲をこの記載範囲にのみ限定する趣旨ではない。   The prescription of the tablet containing the salt of esomeprazole which suppressed moisture absorption of the present invention and its production method will be described in detail below. However, the following description is an example for explaining the present invention, and is not intended to limit the technical scope of the present invention only to this description range.

＜原薬＞
本発明の錠剤は原薬としてエソメプラゾールの塩を含み、好ましくはエソメプラゾールの金属塩（望ましくはアルカリ土類金属塩）であり、より好ましくはエソメプラゾールのマグネシウム塩であり、最も好ましくはエソメプラゾールマグネシウム水和物である。エソメプラゾールの塩のメディアン径（ｄ５０）は０．１〜５０．０μｍが好ましく、より好ましくは１．０〜２０．０μｍである。エソメプラゾールの塩は、必要に応じて適宜乾式又は湿式粉砕を行い、任意の粒子径に調整することも可能である。エソメプラゾールの塩は素錠（フィルムコーティング層で覆われていない錠剤を指す。以下同じ。）部分に含有され、素錠の全重量に対して、５．０重量％以上、６．０〜５０．０重量％、好ましくは８．０〜３５．０重量％の範囲内で素錠中に含有される。 <Drug substance>
The tablet of the present invention contains a salt of esomeprazole as an active ingredient, preferably a metal salt of esomeprazole (desirably an alkaline earth metal salt), more preferably a magnesium salt of esomeprazole, most preferably Is esomeprazole magnesium hydrate. The median diameter (d 50 ) of the salt of esomeprazole is preferably 0.1 to 50.0 μm, and more preferably 1.0 to 20.0 μm. The salt of esomeprazole can be adjusted to an arbitrary particle size by appropriately performing dry or wet pulverization as necessary. The salt of esomeprazole is contained in an uncoated tablet (refers to a tablet not covered with a film coating layer; the same shall apply hereinafter), and is 5.0% by weight or more and 6.0 to 6.0% based on the total weight of the uncoated tablet. It is contained in the uncoated tablet within the range of 50.0% by weight, preferably 8.0 to 35.0% by weight.

＜錠剤の形態＞
本発明の錠剤は、素錠のままであることも可能であるが、コーティング剤を含むフィルムコーティング層で素錠を被覆してフィルムコーティング錠とすることが実用上好ましい。素錠は打錠等により圧縮成形された錠剤である。本発明の錠剤の形状は、円形錠、円形Ｒ錠、円形隅角錠、円形２段Ｒ錠や異形錠（楕円錠等）等のいずれの形状でもよい。 <Tablet form>
The tablet of the present invention can be an uncoated tablet, but it is practically preferable to coat the uncoated tablet with a film coating layer containing a coating agent to form a film-coated tablet. An uncoated tablet is a tablet that is compression-molded by tableting or the like. The shape of the tablet of the present invention may be any shape such as a circular tablet, a circular R tablet, a circular corner tablet, a circular two-stage R tablet, and an irregular tablet (such as an elliptical tablet).

＜水分吸湿量の抑制：吸湿性が低い添加剤＞
本発明の錠剤は、水分吸湿量が抑制されたものであることが好ましいと考えられるため、吸湿性が低い添加剤を多い割合で素錠中に含むことが好ましい。そのため、賦形剤は吸湿性が低い添加剤であることが好ましい。吸湿性が低い添加剤として具体的には、無水乳糖、Ｄ−マンニトール、キシリトール、マルチトール、マルトース、白糖、イソマルト、スクロース、トレハロース等が挙げられ、好ましくは無水乳糖、Ｄ-マンニトール、キシリトール、マルチトール、マルトース、白糖、イソマルト、スクロース、トレハロースから選択され、より好ましくはＤ-マンニトール、キシリトール、白糖、スクロース、トレハロースから選択され、最も好ましくはＤ-マンニトールである。吸湿性が低い添加剤は、結合水を含むもの（水和物等）ではないことが望ましい。
本発明における吸湿性が低い添加剤は、温度２５度相対湿度７５％の条件下において１０．０％未満、より好ましくは３．０％未満、更により好ましくは１．５％未満の平衡含水率（％（ｗ／ｗ））を示す。平衡含水率は、温度２５度相対湿度７５％の条件下で水分を吸湿して平衡状態に入った時の添加剤の重量をＡとし、前記添加剤を１０５℃１時間の乾燥条件下（乃至はそれと同等の乾燥条件下）で乾燥後の重量をＢとすると、式：平衡含水率（％）＝｛（Ａ−Ｂ）／Ａ｝×１００（％）により求められる。
吸湿性が低い添加剤は、素錠の全重量に対して５０．０重量％以上、好ましくは６０．０重量％以上、より好ましくは６５．０〜９０．０重量％の範囲内で素錠中に含有される。エソメプラゾールの塩並びに吸湿性が低い添加剤は、素錠の全重量に対して７０．０重量％以上、好ましくは８０．０重量％以上、より好ましくは８５．０重量％以上、更により好ましくは８７．０〜９８．０重量％の範囲内で素錠中に含有される。
本発明に係る素錠は、自由水を素錠中に低く含むことが好ましいため、乾燥減量値（％（ｗ／ｗ））が１．８重量％以下、好ましくは１．０重量％以下、より好ましくは０．５重量％以下である。乾燥減量値は、式：乾燥減量値（％）＝｛（乾燥前の素錠−乾燥後の素錠）／乾燥前の素錠｝×１００（％）により求められる（乾燥は例えば１０５℃１時間の乾燥条件下（乃至はそれと同等の乾燥条件下）で行われる。）。 <Inhibition of moisture absorption: additive with low hygroscopicity>
Since it is considered that the moisture absorption amount of the tablet of the present invention is preferably suppressed, it is preferable that the uncoated tablet contains an additive having a low hygroscopicity in a large proportion. Therefore, the excipient is preferably an additive having low hygroscopicity. Specific examples of the additive having low hygroscopicity include anhydrous lactose, D-mannitol, xylitol, maltitol, maltose, sucrose, isomalt, sucrose, trehalose, etc., preferably anhydrous lactose, D-mannitol, xylitol, maltitol Selected from tall, maltose, sucrose, isomalt, sucrose and trehalose, more preferably selected from D-mannitol, xylitol, sucrose, sucrose and trehalose, most preferably D-mannitol. The additive having low hygroscopicity is desirably not one containing bound water (such as a hydrate).
The additive having low hygroscopicity in the present invention has an equilibrium water content of less than 10.0%, more preferably less than 3.0%, and even more preferably less than 1.5% under the condition of a temperature of 25 degrees and a relative humidity of 75%. (% (W / w)). Equilibrium moisture content is defined as the weight of the additive when the moisture is absorbed under the condition of a temperature of 25 ° C. and a relative humidity of 75% to enter the equilibrium state. Is obtained by the following formula: Equilibrium moisture content (%) = {(A−B) / A} × 100 (%).
The additive having low hygroscopicity is 50.0% by weight or more, preferably 60.0% by weight or more, more preferably 65.0 to 90.0% by weight based on the total weight of the uncoated tablet. Contained in. The salt of esomeprazole and the additive having low hygroscopicity are 70.0% by weight or more, preferably 80.0% by weight or more, more preferably 85.0% by weight or more, and still more based on the total weight of the uncoated tablet. Preferably, it is contained in the uncoated tablet within the range of 87.0 to 98.0% by weight.
Since the uncoated tablet according to the present invention preferably contains free water low in the uncoated tablet, the loss on drying value (% (w / w)) is 1.8% by weight or less, preferably 1.0% by weight or less, More preferably, it is 0.5% by weight or less. The dry weight loss value is determined by the formula: dry weight loss value (%) = {(plain tablet before drying−plain tablet after drying) / plain tablet before drying} × 100 (%) (drying is, for example, 105 ° C. (It is carried out under dry conditions for a period of time (or under equivalent dry conditions).)

＜吸湿量の抑制：吸湿性が高い添加剤等＞
本発明の錠剤は、吸湿量が抑制されたものであることが好ましいと考えられるため、吸湿性が高い添加剤の量はより低い割合で含まれるように製造されることが好ましい。本発明における吸湿性が高い添加剤は、温度２５度相対湿度７５％の条件下において１０．０％以上、本発明により不適には１５．０％以上、本発明に更により不適には２０．０％以上の平衡含水率（％（ｗ／ｗ））を示す。吸湿性が高い添加剤としては、トウモロコシデンプン、バレイショデンプン、コムギデンプン、コメデンプン、デンプングリコール酸ナトリウム、低置換度ヒドロキシプロピルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム、カルボシキメチルスターチナトリウム、ポビドン、クロスポビドン、部分アルファー化デンプン、ヒドロキシプロピルスターチ、クロスカルメロースナトリウム、軽質無水ケイ酸、含水二酸化ケイ素、ケイ酸カルシウム、合成ケイ酸アルミニウム、メタケイ酸アルミン酸マグネシウム、炭酸水素ナトリウム等が挙げられ、本発明に特に不適にはトウモロコシデンプン、バレイショデンプン、コムギデンプン、コメデンプン、デンプングリコール酸ナトリウム、ポビドン、クロスポビドン、カルメロース、カルメロースカルシウム、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、クロスカルメロースナトリウムから選択され、本発明に最も不適にはデンプングリコール酸ナトリウム、ポビドン、クロスポビドン、クロスカルメロースナトリウムから選択される。
吸湿性が高い添加剤（望ましくは水和物である添加剤と併せて）は素錠の全重量に対して１５．０重量％以下、好ましくは１０．０重量％以下、より好ましくは６．０重量％以下の範囲内で素錠中に含まれる乃至は素錠中に含まれない。尚、吸湿性が高い添加剤が上記の最も不適なものである場合においては、吸湿性が高い添加剤が素錠中に含まれないことが最も好ましい。吸湿性が高い添加剤は、化学的な安定性以外の品質（特に崩壊性や溶出性）を望ましいものにするため、上記いずれかの範囲内にて或る程度の量（０．５重量％以上、好ましくは２．０重量％以上、より好ましくは４．０重量％以上）を素錠中に含むことが必要となる場合が多い。 <Suppression of moisture absorption: Additives with high hygroscopicity>
Since it is considered that the tablet of the present invention preferably has a reduced amount of moisture absorption, it is preferably manufactured so that the amount of the additive having a high moisture absorption is contained at a lower ratio. The additive having high hygroscopicity in the present invention is 10.0% or more under conditions of a temperature of 25 degrees relative humidity of 75%, 15.0% or more inappropriate according to the present invention, and 20. An equilibrium water content (% (w / w)) of 0% or more is shown. Highly hygroscopic additives include corn starch, potato starch, wheat starch, rice starch, sodium starch glycolate, low substituted hydroxypropylcellulose, carmellose, carmellose calcium, carmellose sodium, carboxymethyl starch sodium, povidone , Crospovidone, partially pregelatinized starch, hydroxypropyl starch, croscarmellose sodium, light anhydrous silicic acid, hydrous silicon dioxide, calcium silicate, synthetic aluminum silicate, magnesium aluminate metasilicate, sodium bicarbonate, etc. Particularly unsuitable for the present invention are corn starch, potato starch, wheat starch, rice starch, sodium starch glycolate, povidone, crospovid , Carmellose, carmellose calcium, low-substituted hydroxypropylcellulose, hydroxypropyl starch, croscarmellose sodium, and most inappropriately selected from sodium starch glycolate, povidone, crospovidone, croscarmellose sodium The
The additive having high hygroscopicity (preferably together with an additive which is a hydrate) is 15.0% by weight or less, preferably 10.0% by weight or less, more preferably 6. It is contained in the uncoated tablet within the range of 0% by weight or less or not contained in the uncoated tablet. In the case where the additive having high hygroscopicity is the most unsuitable, it is most preferable that the additive having high hygroscopicity is not contained in the uncoated tablet. Additives with high hygroscopicity may have a certain amount (0.5% by weight) within any of the above ranges in order to make the quality (especially disintegration and dissolution) other than chemical stability desirable. As described above, it is often necessary to contain 2.0 wt% or more, more preferably 4.0 wt% or more) in the uncoated tablet.

＜塩基性の添加剤＞
本発明の錠剤においては、塩基性の添加剤を含む必要が特に無く、素錠の全重量に対して１．０重量％以下の範囲内で素錠中に含まれる乃至は素錠中に含まれないことが好ましい。本明細書における塩基性の添加剤は２．０％濃度（ｗ／ｗ）の水溶液のｐＨが８．０以上、より本発明に不適には９．０以上、更に不適には１０．０以上の範囲を示すものである。塩基性の添加剤として、Ｌ−アルギニン、Ｌ−リジン、メグルミン等の有機化合物や、炭酸マグネシウム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸水素カリウム、炭酸カリウム、炭酸カルシウム、炭酸アンモニウム、無水リン酸水素カルシウム、リン酸水素二カリウム、ケイ酸カルシウム、ケイ酸マグネシウム、ケイ酸アルミン酸マグネシウム、メタケイ酸アルミン酸マグネシウム、酸化マグネシウム、水酸化アルミニウム、水酸化ナトリウム、水酸化カルシウム、水酸化カリウム等の無機化合物が挙げられ、本発明により不適には炭酸マグネシウム、炭酸水素ナトリウム、炭酸ナトリウム、炭酸水素カリウム、炭酸カリウム、炭酸カルシウム、炭酸アンモニウムから選択され、本発明に更により不適には炭酸マグネシウムである。 <Basic additive>
The tablet of the present invention does not need to contain a basic additive, and is contained in the uncoated tablet or contained in the uncoated tablet within a range of 1.0% by weight or less with respect to the total weight of the uncoated tablet. Preferably not. In the present specification, the basic additive has a 2.0% (w / w) aqueous solution having a pH of 8.0 or higher, more preferably 9.0 or higher, and further inappropriate 10.0 or higher. The range is shown. As basic additives, organic compounds such as L-arginine, L-lysine and meglumine, magnesium carbonate, sodium hydrogen carbonate, sodium carbonate, potassium hydrogen carbonate, potassium carbonate, calcium carbonate, ammonium carbonate, anhydrous calcium hydrogen phosphate Inorganic compounds such as dipotassium hydrogen phosphate, calcium silicate, magnesium silicate, magnesium aluminate silicate, magnesium aluminate metasilicate, magnesium oxide, aluminum hydroxide, sodium hydroxide, calcium hydroxide, potassium hydroxide Selected from magnesium carbonate, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium carbonate, ammonium carbonate, and more inappropriately suitable for the present invention is magnesium carbonate.

本発明の錠剤を製造するためには、一般的に使用されている賦形剤、結合剤、崩壊剤、滑沢剤、コーティング剤等の添加剤を使用することができる。本発明に係る素錠は、原薬、賦形剤、崩壊剤、結合剤、及び滑沢剤からなることが簡易に製造する上で好ましく、各添加剤は１〜２種類、好ましくは１種類の物質である（各添加剤である化合物は他の添加剤を兼用しないことが基本だが、製剤構成上乃至は製剤化過程上で物理的乃至は時期的な隔たりをもって用いられる場合はこの限りではない。）。
尚、本明細書において、各種添加剤（賦形剤、結合剤、崩壊剤、滑沢剤等）の語句の解釈は其々、製剤化において其の添加剤としての役割を発揮することが必須に期待されて使用されるもので結果的にも其の添加剤としての役割が発揮されたもの、と解することが好ましい。また当然であるが、本明細書における添加剤の語句の解釈において原薬が含まれることはない。 In order to produce the tablet of the present invention, commonly used additives such as excipients, binders, disintegrants, lubricants, and coating agents can be used. The uncoated tablet according to the present invention is preferably made of a drug substance, an excipient, a disintegrant, a binder, and a lubricant for easy production, and each additive has 1 to 2 types, preferably 1 type. (It is basic that each additive compound is not combined with other additives. However, if it is used with physical or temporal differences in the formulation or formulation process, this is not necessary. Absent.).
In addition, in this specification, it is indispensable that the interpretations of the phrases of various additives (excipients, binders, disintegrants, lubricants, etc.) each play a role as the additive in formulation. It is preferable to understand that it is used in anticipation of the above, and as a result, its role as an additive is exhibited. Of course, the drug substance is not included in the interpretation of the term additive in this specification.

賦形剤として、具体的には乳糖水和物、無水乳糖、結晶セルロース、Ｄ-マンニトール、エリスリトール、キシリトール、ソルビトール、マルチトール、マルトース、白糖、ショ糖、ブドウ糖、イソマルト、スクロース、トレハロース、トウモロコシデンプン、バレイショデンプン、コメデンプン、コムギデンプン、ヒドロキシプロピルスターチ、アルファー化デンプン、部分アルファー化デンプン、カルボキシメチルスターチナトリウム、デキストリン、粉末還元麦芽糖水アメ等を挙げる事ができ、好ましくは無水乳糖、Ｄ-マンニトール、キシリトール、マルチトール、マルトース、白糖、イソマルト、スクロース、トレハロースから選択され、より好ましくはＤ-マンニトール、キシリトール、白糖、スクロース、トレハロースから選択され、最も好ましくはＤ-マンニトールである。賦形剤は、素錠の全重量に対して１０．０〜９５．０重量％、好ましくは３５．０〜９０．０重量％の範囲内で素錠中に含有される。   Specific excipients include lactose hydrate, anhydrous lactose, crystalline cellulose, D-mannitol, erythritol, xylitol, sorbitol, maltitol, maltose, sucrose, sucrose, glucose, isomalt, sucrose, trehalose, corn starch Potato starch, rice starch, wheat starch, hydroxypropyl starch, pregelatinized starch, partially pregelatinized starch, sodium carboxymethyl starch, dextrin, powdered reduced maltose water candy, etc., preferably anhydrous lactose, D-mannitol , Xylitol, maltitol, maltose, sucrose, isomalt, sucrose, trehalose, more preferably selected from D-mannitol, xylitol, sucrose, sucrose, trehalose , Most preferably D- mannitol. The excipient is contained in the uncoated tablet within a range of 10.0 to 95.0% by weight, preferably 35.0 to 90.0% by weight, based on the total weight of the uncoated tablet.

結合剤として、具体的にはヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース（ヒプロメロース）、メチルセルロース、ポビドン、エチルセルロース、ポリビニルアルコール、ポリビニルアルコール・アクリル酸・メタクリル酸メチル共重合体、ポリエチレングリコール、メタクリル酸コポリマー、アクリル酸エチル・メタクリル酸メチルコポリマー分散液等を挙げる事ができ、好ましくはヒプロメロースである。結合剤は、素錠の全重量に対して好ましくは０．１〜８．０重量％の範囲内で素錠中に含有される。   Specific binders include hydroxypropylcellulose, hydroxypropylmethylcellulose (hypromellose), methylcellulose, povidone, ethylcellulose, polyvinyl alcohol, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyethylene glycol, methacrylic acid copolymer, acrylic acid. Examples thereof include an ethyl / methyl methacrylate copolymer dispersion, and hypromellose is preferable. The binder is preferably contained in the uncoated tablet within a range of 0.1 to 8.0% by weight with respect to the total weight of the uncoated tablet.

崩壊剤として、具体的には低置換度ヒドロキシプロピルセルロース、カルメロース、カルメロースカルシウム、カルメロースナトリウム、ヒドロキシプロピルスターチ、カルボキシメチルスターチナトリウム、クロスポビドン、カンテン末等を挙げる事ができ、好ましくは低置換度ヒドロキシプロピルセルロースである。崩壊剤は、素錠の全重量に対して１．０〜２０．０重量％、好ましくは２．０〜１０．０重量％、より好ましくは３．０〜６．０重量％の範囲内で素錠中に含有される。   Specific examples of the disintegrant include low-substituted hydroxypropyl cellulose, carmellose, carmellose calcium, carmellose sodium, hydroxypropyl starch, carboxymethyl starch sodium, crospovidone, agar powder, etc. Degree of hydroxypropyl cellulose. The disintegrant is in the range of 1.0 to 20.0% by weight, preferably 2.0 to 10.0% by weight, more preferably 3.0 to 6.0% by weight, based on the total weight of the uncoated tablet. Contained in uncoated tablets.

滑沢剤として、具体的には軽質無水ケイ酸、ステアリン酸マグネシウム、ステアリン酸カルシウム、フマル酸ステアリルナトリウム、タルク、硬化油等を挙げる事ができ、好ましくはステアリン酸マグネシウムである。滑沢剤は、素錠の全重量に対して好ましくは０．１〜５．０重量％の範囲内で素錠中に含有される。   Specific examples of the lubricant include light anhydrous silicic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, talc, hydrogenated oil, etc., preferably magnesium stearate. The lubricant is contained in the uncoated tablet preferably in the range of 0.1 to 5.0% by weight with respect to the total weight of the uncoated tablet.

コーティング剤として、具体的にはヒドロキシプロピルメチルセルロース（ヒプロメロース）、エチルセルロース、ヒドロキシメチルセルロース、ヒドロキシプロピルセルロース、ポリビニルアルコール・アクリル酸・メタクリル酸メチル共重合体、ポリビニルアルコール、ポリエチレングリコール、メタクリル酸コポリマー、アクリル酸エチル・メタクリル酸メチルコポリマー分散液、タルク等を挙げる事ができ、好ましくはヒプロメロース、メタクリル酸コポリマー、タルク、クエン酸トリエチルから選ばれる。コーティング剤は、素錠の全重量に対して１．０〜５０．０重量％、好ましくは２．０〜１０．０重量％の範囲内で錠剤中に含有される。
フィルムコーティング層は２層以上が素錠の周囲に施されて、その内（望ましくは最も内側に位置する層を除く。）の１層は腸溶性のコーティング剤を含むフィルムコーティング層であることが望ましい。腸溶性のコーティング剤として、具体的にはメタクリル酸コポリマー（メタクリル酸コポリマーＬ、メタクリル酸コポリマーＬＤ（固形分）、メタクリル酸コポリマーＳ等）、ヒプロメロースフタル酸エステル、ヒプロメロース酢酸エステルコハク酸エステル、カルボキシメチルエチルセルロース等を挙げる事ができ、好ましくはメタクリル酸コポリマーである。 Specific examples of coating agents include hydroxypropylmethylcellulose (hypromellose), ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, polyvinyl alcohol, polyethylene glycol, methacrylic acid copolymer, ethyl acrylate -Methyl methacrylate copolymer dispersion, talc and the like can be mentioned, and preferably selected from hypromellose, methacrylic acid copolymer, talc and triethyl citrate. The coating agent is contained in the tablet in the range of 1.0 to 50.0% by weight, preferably 2.0 to 10.0% by weight, based on the total weight of the uncoated tablet.
Two or more film coating layers are provided around the uncoated tablet, and one of them (desirably excluding the innermost layer) is a film coating layer containing an enteric coating agent. desirable. Examples of enteric coating agents include methacrylic acid copolymers (methacrylic acid copolymer L, methacrylic acid copolymer LD (solid content), methacrylic acid copolymer S, etc.), hypromellose phthalate ester, hypromellose acetate succinate, Examples thereof include carboxymethyl ethyl cellulose, and a methacrylic acid copolymer is preferable.

遮光剤として、具体的には酸化チタン、黄色三二酸化鉄、三二酸化鉄、黒酸化鉄、黄酸化鉄、褐色酸化鉄、食用黄色４号、食用黄色５号、食用黄色４号アルミニウムレーキ、食用赤色２号、食用赤色３号、食用赤色１０２号等を挙げる事ができ、好ましくは酸化チタン、黄色三二酸化鉄、三二酸化鉄から選択され、より好ましくは酸化チタン及び黄色三二酸化鉄又は三二酸化鉄である。遮光剤は、素錠の全重量に対して０．０５重量％以上、好ましくは０．２重量％以上、より好ましくは０．２〜１０．０重量％、更により好ましくは０．５〜３．０重量％の範囲で錠剤中に含有される。遮光剤はフィルムコーティング層に含まれることが好ましい。フィルムコーティング層１００．０重量部に対して遮光剤は１．０重量部以上、好ましくは３．０重量部以上、より好ましくは３．０〜１０．０重量部の範囲内でフィルムコーティング層中に含有される。   Specifically, as a light-shielding agent, titanium oxide, yellow ferric oxide, ferric oxide, black iron oxide, yellow iron oxide, brown iron oxide, edible yellow No. 4, edible yellow No. 5, edible yellow No. 4 aluminum lake, edible Red No. 2, Edible Red No. 3, Edible Red No. 102, etc. can be mentioned, preferably selected from titanium oxide, yellow iron sesquioxide, iron sesquioxide, more preferably titanium oxide and yellow iron sesquioxide or sesquioxide. It is iron. The light-shielding agent is 0.05% by weight or more, preferably 0.2% by weight or more, more preferably 0.2 to 10.0% by weight, still more preferably 0.5 to 3%, based on the total weight of the uncoated tablet. It is contained in the tablet in the range of 0.0% by weight. The light-shielding agent is preferably contained in the film coating layer. The light-shielding agent is 1.0 part by weight or more with respect to 100.0 parts by weight of the film coating layer, preferably 3.0 parts by weight or more, more preferably within the range of 3.0 to 10.0 parts by weight in the film coating layer. Contained in

本発明の錠剤は、エソメプラゾールの塩を含む顆粒を含有するものであることが好ましい。当該顆粒は、素錠の全重量に対して５０．０重量％以上、好ましくは７０．０〜９９．８重量％、より好ましくは９０．０〜９９．０重量％の範囲で錠剤中に含有され、エソメプラゾールの塩、１〜２種類（好ましくは１種類）の賦形剤、１〜２種類（好ましくは１種類）の崩壊剤及び１〜２種類（好ましくは１種類）の結合剤からなるものであることが好ましい。   The tablet of the present invention preferably contains granules containing a salt of esomeprazole. The granule is contained in the tablet in an amount of 50.0% by weight or more, preferably 70.0 to 99.8% by weight, more preferably 90.0 to 99.0% by weight, based on the total weight of the uncoated tablet. Esomeprazole salt, 1 to 2 (preferably 1) excipient, 1 to 2 (preferably 1) disintegrant and 1 to 2 (preferably 1) binder It is preferable that it consists of.

本発明の錠剤は、一般的な製造方法によって作成することが可能であり、例えば以下の製造方法によって作成することが可能である。
まず、原薬、賦形剤、崩壊剤等を混合した粉末に水等に溶解した結合剤を加えて流動層造粒を行って造粒物を製造する。そして、得られた造粒物を整粒（乾式解砕等）した後に、滑沢剤等と混合して打錠機によって圧縮成形して錠剤（素錠）とする。更に所望によって、得られた素錠にフィルムコーティング層を施すことが可能である。エソメプラゾールの塩を含有する錠剤においては、素錠又はフィルムコーティング錠に腸溶性のコーティング剤を含むフィルムコーティング層が施されている等の工夫があることが実用上望まれる。本発明の素錠を打錠して製造する際の打圧は、３００〜１５００ｋｇｆ、好ましくは４００〜１２００ｋｇｆの範囲内の任意の数値から選ばれる。 The tablet of the present invention can be prepared by a general manufacturing method, for example, by the following manufacturing method.
First, a granulated product is produced by adding a binder dissolved in water or the like to a powder in which a drug substance, an excipient, a disintegrant and the like are mixed, and performing fluidized bed granulation. The obtained granulated product is sized (dry pulverization, etc.), mixed with a lubricant, etc., and compressed by a tableting machine to obtain tablets (plain tablets). Further, if desired, a film coating layer can be applied to the obtained uncoated tablet. In the tablet containing the salt of esomeprazole, it is practically desired that there is a device such as a film coating layer containing an enteric coating agent applied to the uncoated tablet or the film coated tablet. The punching pressure when tableting and manufacturing the uncoated tablet of the present invention is selected from any numerical value within the range of 300 to 1500 kgf, preferably 400 to 1200 kgf.

また、包装用シートとアルミ箔等で錠剤を挟んで覆い、加熱シールすることで、本発明の錠剤を含むＰＴＰシート製品を得ることは可能である。其の包装用シートに使用される具体的な素材としては、ポリ塩化ビニル、ポリプロピレン、ポリ塩化ビニリデン、ポリクロロトリフルオロエチレン等が挙げられる。尚、湿度に対する本発明の錠剤の安定性を改善するためには、乾燥機能を有した素材を用いてＰＴＰシート製品を製造したり、ＰＴＰシート製品をアルミピロー包装したり、乾燥剤を錠剤と共に瓶に封入する等の周知の方法を行うことが可能である。   Further, it is possible to obtain a PTP sheet product including the tablet of the present invention by covering the tablet with a packaging sheet and aluminum foil or the like, and heat-sealing. Specific materials used for the packaging sheet include polyvinyl chloride, polypropylene, polyvinylidene chloride, polychlorotrifluoroethylene and the like. In addition, in order to improve the stability of the tablet of the present invention against humidity, a PTP sheet product is manufactured using a material having a drying function, the PTP sheet product is packaged in an aluminum pillow, or a desiccant is combined with the tablet. It is possible to perform a known method such as sealing in a bottle.

以下に実施例等により本発明を説明するが、本発明はこれらの実施例等に限定されるものではない。   EXAMPLES The present invention will be described below with reference to examples and the like, but the present invention is not limited to these examples and the like.

エソメプラゾールマグネシウム水和物２２３．０ｇ、Ｄ−マンニトール６８２．０ｇ、及び低置換度ヒドロキシプロピルセルロース３０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース５０．０ｇを精製水９５０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内２９５．５ｇにステアリン酸マグネシウム４．５ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて６００ｋｇｆの打圧で打錠して１錠重量１００．０ｍｇの素錠（円形錠、直径６．５ｍｍ、厚さ３．１ｍｍ）を得た。   Esomeprazole magnesium hydrate 223.0 g, D-mannitol 682.0 g, and low-substituted hydroxypropylcellulose 30.0 g were charged into a fluid bed granulator (manufactured by Paulec: MP-01 type) and mixed. Then, fluidized bed granulation was performed by spraying and drying a solution obtained by dissolving 50.0 g of hypromellose in 950.0 g of purified water. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 4.5 g of magnesium stearate was added to 295.5 g of the granulated product thus obtained and mixed in a polyethylene bag. Next, this mixture was compressed with a tableting force of 600 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet (round tablet, diameter 6.5 mm, thickness) of 100.0 mg. 3.1 mm).

実施例１で得られた素錠をコーティング機（パウレック社製：ＤＲＣ−２００型）に投入し、これに、予めヒプロメロース７２．０ｇ、及びタルク８．０ｇを精製水６４８．０ｇに加え、均一分散させた液を噴霧し、１錠質量１０４．０ｍｇになるまでコーティングし、乾燥してコーティング錠を得た。
其のコーティング錠を更に、メタクリル酸コポリマーＬＤの３０％懸濁液２９０．０ｇ（固形分：８７．０ｇ）、タルク３５．０ｇ、クエン酸トリエチル１０．０ｇ、及び酸化チタン８．０ｇを精製水５９０．０ｇに加え、均一分散させた液を噴霧し、１錠質量１１８．０ｍｇになるまでコーティングし、乾燥して２層コーティング錠を得た。 The uncoated tablet obtained in Example 1 was put into a coating machine (manufactured by POWREC: DRC-200 type). To this, 72.0 g of hypromellose and 8.0 g of talc were added in advance to 648.0 g of purified water. The dispersed liquid was sprayed, coated to a mass of 104.0 mg per tablet, and dried to obtain coated tablets.
The coated tablet was further purified with 290.0 g of 30% suspension of methacrylic acid copolymer LD (solid content: 87.0 g), 35.0 g of talc, 10.0 g of triethyl citrate, and 8.0 g of titanium oxide in purified water. In addition to 590.0 g, the uniformly dispersed solution was sprayed, coated to a mass of 118.0 mg per tablet, and dried to obtain two-layer coated tablets.

［比較例Ａ１］
エソメプラゾールマグネシウム水和物２２３．０ｇ、乳糖水和物６８７．０ｇ、トウモロコシデンプン２００．０ｇ、及び低置換度ヒドロキシプロピルセルロース４０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒドロキシプロピルセルロース４０．０ｇを精製水７６０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内２３８．０ｇにステアリン酸マグネシウム２．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。 [Comparative Example A1]
Esomeprazole magnesium hydrate 223.0 g, lactose hydrate 687.0 g, corn starch 200.0 g, and low-substituted hydroxypropylcellulose 40.0 g were fluidized bed granulator (manufactured by Paulek: MP-01 type) ) And mixed, and a fluid obtained by dissolving 40.0 g of hydroxypropylcellulose in 760.0 g of purified water was sprayed and dried to perform fluidized bed granulation. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 2.0 g of magnesium stearate was added to 238.0 g of the sized product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a weight of 120.0 mg (round tablet, diameter 7.0 mm, thickness) 3.3 mm).

［比較例Ｂ１］
エソメプラゾールマグネシウム水和物２２３．０ｇ、Ｄ−マンニトール６３２．０ｇ、低置換度ヒドロキシプロピルセルロース３０．０ｇ、及び炭酸マグネシウム５０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース５０．０ｇを精製水９５０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内２９５．５ｇにステアリン酸マグネシウム４．５ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて６００ｋｇｆの打圧で打錠して１錠重量１００．０ｍｇの素錠（円形錠、直径６．５ｍｍ、厚さ３．１ｍｍ）を得た。 [Comparative Example B1]
Esomeprazole magnesium hydrate 223.0 g, D-mannitol 632.0 g, low-substituted hydroxypropylcellulose 30.0 g, and magnesium carbonate 50.0 g were fluidized bed granulator (manufactured by Paulec: MP-01 type) Was added to and mixed, and fluidized bed granulation was performed by spraying and drying a solution obtained by dissolving 50.0 g of hypromellose in 950.0 g of purified water. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 4.5 g of magnesium stearate was added to 295.5 g of the granulated product thus obtained and mixed in a polyethylene bag. Next, this mixture was compressed with a tableting force of 600 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet (round tablet, diameter 6.5 mm, thickness) of 100.0 mg. 3.1 mm).

［比較例Ｂ２］
エソメプラゾールマグネシウム水和物２２３．０ｇ、Ｄ−マンニトール６３２．０ｇ、低置換度ヒドロキシプロピルセルロース３０．０ｇ、及び酸化マグネシウム５０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース５０．０ｇを精製水９５０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内２９５．５ｇにステアリン酸マグネシウム４．５ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて６００ｋｇｆの打圧で打錠して１錠重量１００．０ｍｇの素錠（円形錠、直径６．５ｍｍ、厚さ３．１ｍｍ）を得た。 [Comparative Example B2]
Esomeprazole magnesium hydrate 223.0 g, D-mannitol 632.0 g, low-substituted hydroxypropylcellulose 30.0 g, and magnesium oxide 50.0 g were fluidized bed granulator (manufactured by Paulec: MP-01 type) Was added to and mixed, and fluidized bed granulation was performed by spraying and drying a solution obtained by dissolving 50.0 g of hypromellose in 950.0 g of purified water. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 4.5 g of magnesium stearate was added to 295.5 g of the granulated product thus obtained and mixed in a polyethylene bag. Next, this mixture was compressed with a tableting force of 600 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet (round tablet, diameter 6.5 mm, thickness) of 100.0 mg. 3.1 mm).

実施例１、２及び比較例Ａ１、Ｂ１、Ｂ２で得られた各々の錠剤の処方は下記の表１に一覧して示す。   The prescriptions of the tablets obtained in Examples 1 and 2 and Comparative Examples A1, B1, and B2 are listed in Table 1 below.

Figure 2018095632
Figure 2018095632

〔試験例１〕過酷な保存条件下での原薬の安定性試験
実施例１〜３及び比較例Ａ１、Ｂ１、Ｂ２の各錠剤、エソメプラゾールマグネシウム水和物を含有する或る製剤処方のカプセル剤を、温度５０℃の密封条件下又は温度５０℃相対湿度７５％の開放条件下で７日間保存した後に、総類縁体の量を測定した。其の測定は高速液体クロマトグラフィー法（定量方法は面積百分率法を使用した。）によって行った。上記の測定結果は下記の表２に示す。 [Test Example 1] Stability test of drug substance under harsh storage conditions Each tablet of Examples 1 to 3 and Comparative Examples A1, B1 and B2, and a pharmaceutical formulation containing esomeprazole magnesium hydrate After the capsules were stored for 7 days under sealed conditions at a temperature of 50 ° C. or under open conditions at a temperature of 50 ° C. and a relative humidity of 75%, the amount of total analogues was measured. The measurement was performed by the high performance liquid chromatography method (quantitative method used area percentage method). The measurement results are shown in Table 2 below.

Figure 2018095632
Figure 2018095632

〔試験例２〕乾燥減量値の測定
実施例１及び比較例Ａ１、Ｂ１、Ｂ２に記載された製造直後の各整粒品１０ｇにつき、赤外水分計(ケット科学研究所製、ＦＤ−７２０型)を用いて、乾燥温度：８０℃で測定時間：１５分間の設定条件下での乾燥減量値（％）を測定した。各整粒品の乾燥減量値（％）は、下記の表３に示す。乾燥温度とは、試料にかかる温度ではなく赤外水分計の温度センサが感知した温度となる（赤外水分計ＦＤ−７２０取扱説明書３４ページの記載を参考。） [Test Example 2] Measurement of loss on drying value For each sized product 10 g immediately after production described in Example 1 and Comparative Examples A1, B1, and B2, an infrared moisture meter (FD-720, manufactured by Kett Science Laboratory) ) Was used to measure the loss on drying (%) under the set conditions of drying temperature: 80 ° C. and measurement time: 15 minutes. The loss on drying value (%) of each sized product is shown in Table 3 below. The drying temperature is not the temperature applied to the sample but the temperature sensed by the temperature sensor of the infrared moisture meter (refer to the description on page 34 of the instruction manual for the infrared moisture meter FD-720).

Figure 2018095632
Figure 2018095632

表２において、吸湿性が低い添加剤を非常に多量の割合で素錠に含む実施例１、２の錠剤は、吸湿性が高い添加剤を多量の割合で含む比較例Ａ１の錠剤に比べて保存後の総類縁体の発生量が顕著に低いことが示され、特に開放条件下（吸湿しやすい条件下）でより顕著に低いことが示された。
よって、吸湿性が低い添加剤を多量の割合で含むことはエソメプラゾールの化学的な安定性を顕著に改善することが示唆された。
また表３において、製造直後の実施例１の整粒品は乾燥減量値が低いことが確認され、製造直後の実施例１の素錠は自由水を素錠中に低く含むことが示唆された。
比較例Ｂ１や比較例Ｂ２は、安定化剤として塩基性の添加剤である炭酸マグネシウム（比較例Ｂ１）や酸化マグネシウム（比較例Ｂ２）を添加したが、先行文献からの予想に反して、保存後のエソメプラゾール由来の類縁体の発生量が抑制されることは示されず、逆に炭酸マグネシウムによって開放条件下で保存後の化学的な安定性が顕著に低下することが示された。よって本発明の錠剤においては、塩基性の添加剤を含むことを必要としないことが示唆された。また、エソメプラゾールの塩はオメプラゾールと一部異なる物性をもつ可能性も示唆された。 In Table 2, the tablets of Examples 1 and 2 containing a very large amount of additive with low hygroscopicity in the uncoated tablet compared to the tablet of Comparative Example A1 containing large amount of additive with high hygroscopic property. It was shown that the amount of total analogues generated after storage was remarkably low, especially under open conditions (conditions that easily absorb moisture).
Therefore, it was suggested that including a large amount of an additive having low hygroscopicity significantly improves the chemical stability of esomeprazole.
In Table 3, it was confirmed that the granulated product of Example 1 immediately after production had a low loss on drying value, and it was suggested that the uncoated tablet of Example 1 immediately after production contained low free water in the uncoated tablet. .
In Comparative Examples B1 and B2, magnesium carbonate (Comparative Example B1) and magnesium oxide (Comparative Example B2), which are basic additives, were added as stabilizers. It was not shown that the generation amount of the analog derived from esomeprazole later was suppressed, and conversely, it was shown that the chemical stability after storage under open conditions was significantly reduced by magnesium carbonate. Therefore, it was suggested that the tablet of the present invention does not need to contain a basic additive. It was also suggested that the salt of esomeprazole may have some physical properties different from omeprazole.

エソメプラゾールマグネシウム水和物２２３．０ｇ、Ｄ−マンニトール８３２．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。   Esomeprazole magnesium hydrate 223.0 g, D-mannitol 832.0 g, and low-substituted hydroxypropylcellulose 60.0 g were charged into a fluid bed granulator (manufactured by POWREC: MP-01 type) and mixed. Then, fluidized bed granulation was performed by spraying and drying a solution obtained by dissolving 65.0 g of hypromellose in 1120.0 g of purified water. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

Ｄ−マンニトール８３２．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液に、エソメプラゾールマグネシウム水和物２２３．０ｇを懸濁した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。   832.0 g of D-mannitol and 60.0 g of low-substituted hydroxypropylcellulose were introduced into a fluidized bed granulator (manufactured by Paulek: MP-01 type) and mixed, and 65.0 g of hypromellose was added to purified water 1120. Fluidized bed granulation was performed by spraying and drying a liquid in which 223.0 g of esomeprazole magnesium hydrate was suspended in a liquid dissolved in 0.0 g. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

エソメプラゾールマグネシウム水和物１１１．０ｇ、Ｄ−マンニトール９４４．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。   111.0 g of esomeprazole magnesium hydrate, 944.0 g of D-mannitol, and 60.0 g of low-substituted hydroxypropylcellulose were put into a fluidized bed granulator (manufactured by POWREC: MP-01 type) and mixed. Then, fluidized bed granulation was performed by spraying and drying a solution obtained by dissolving 65.0 g of hypromellose in 1120.0 g of purified water. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

Ｄ−マンニトール９４４．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液に、エソメプラゾールマグネシウム水和物１１１．０ｇを懸濁した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。   944.0 g of D-mannitol and 60.0 g of low-substituted hydroxypropylcellulose were put into a fluidized bed granulator (manufactured by Paulek: MP-01 type) and mixed, and 65.0 g of hypromellose was added to purified water 1120. Fluidized-bed granulation was performed by spraying and drying a liquid in which 111.0 g of esomeprazole magnesium hydrate was suspended in a liquid dissolved in 0.0 g. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

実施例４で得られた素錠をコーティング機（パウレック社製：ＤＲＣ−２００型）に投入し、これに、予めヒプロメロース７２．０ｇ、及びタルク８．０ｇを精製水６４８．０ｇに加え、均一分散させた液を噴霧し、１錠質量１２６．０ｍｇになるまでコーティングし、乾燥してコーティング錠を得た。
其のコーティング錠を更に、メタクリル酸コポリマーＬＤの３０％懸濁液２９０．０ｇ（固形分：８７．０ｇ）、タルク３５．０ｇ、クエン酸トリエチル１０．０ｇ、酸化チタン８．０ｇ、及び三二酸化鉄０．０５ｇを精製水５９０．０ｇに加え、均一分散させた液を噴霧し、１錠質量１４０．０ｍｇになるまでコーティングし、乾燥して２層コーティング錠（円形２段Ｒ錠、直径７．３ｍｍ、厚さ３．７ｍｍ）を得た。 The uncoated tablet obtained in Example 4 was put into a coating machine (manufactured by Paulek, Inc .: DRC-200 type). To this, 72.0 g of hypromellose and 8.0 g of talc were added in advance to 648.0 g of purified water. The dispersed liquid was sprayed, coated to a tablet weight of 126.0 mg, and dried to obtain coated tablets.
The coated tablet was further mixed with 290.0 g of a 30% suspension of methacrylic acid copolymer LD (solid content: 87.0 g), 35.0 g of talc, 10.0 g of triethyl citrate, 8.0 g of titanium oxide, and trioxide. Add 0.05 g of iron to 590.0 g of purified water, spray the uniformly dispersed solution, coat it until the weight of one tablet is 140.0 mg, and dry to form a two-layer coated tablet (circular two-stage R tablet, diameter 7 3 mm, thickness 3.7 mm).

実施例６で得られた素錠をコーティング機（パウレック社製：ＤＲＣ−２００型）に投入し、これに、予めヒプロメロース７２．０ｇ、及びタルク８．０ｇを精製水６４８．０ｇに加え、均一分散させた液を噴霧し、１錠質量１２６．０ｍｇになるまでコーティングし、乾燥してコーティング錠を得た。
其のコーティング錠を更に、メタクリル酸コポリマーＬＤの３０％懸濁液２９０．０ｇ（固形分：８７．０ｇ）、タルク３５．０ｇ、クエン酸トリエチル１０．０ｇ、酸化チタン８．０ｇ、及び黄色三二酸化鉄１．２ｇを精製水５９０．０ｇに加え、均一分散させた液を噴霧し、１錠質量１４０．１ｍｇになるまでコーティングし、乾燥して２層コーティング錠（円形２段Ｒ錠、直径７．３ｍｍ、厚さ３．７ｍｍ）を得た。 The uncoated tablet obtained in Example 6 was put into a coating machine (manufactured by Paulek, Inc .: DRC-200 type). To this, 72.0 g of hypromellose and 8.0 g of talc were added in advance to 648.0 g of purified water, and uniform. The dispersed liquid was sprayed, coated to a tablet weight of 126.0 mg, and dried to obtain coated tablets.
The coated tablet was further mixed with 290.0 g of 30% suspension of methacrylic acid copolymer LD (solid content: 87.0 g), 35.0 g of talc, 10.0 g of triethyl citrate, 8.0 g of titanium oxide, and yellow three 1.2 g of iron dioxide is added to 590.0 g of purified water, sprayed with a uniformly dispersed solution, coated to a mass of 140.1 mg per tablet, dried and dried into a two-layer coated tablet (circular two-stage R tablet, diameter 7.3 mm and a thickness of 3.7 mm).

［比較例Ｃ１］
乳糖水和物８３２．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液に、エソメプラゾールマグネシウム水和物２２３．０ｇを懸濁した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。 [Comparative Example C1]
832.0 g of lactose hydrate and 60.0 g of low-substituted hydroxypropyl cellulose were put into a fluidized bed granulator (manufactured by POWREC: MP-01 type) and mixed, and 65.0 g of hypromellose was purified water. Fluidized bed granulation was carried out by spraying and drying a liquid in which 223.0 g of esomeprazole magnesium hydrate was suspended in a liquid dissolved in 1120.0 g. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

［比較例Ｃ２］
乳糖水和物９４４．０ｇ、及び低置換度ヒドロキシプロピルセルロース６０．０ｇを流動層造粒機（パウレック社製：ＭＰ−０１型）に投入して混和させ、これにヒプロメロース６５．０ｇを精製水１１２０．０ｇに溶解した液に、エソメプラゾールマグネシウム水和物１１１．０ｇ懸濁した液を噴霧・乾燥することで流動層造粒を行った。それによって得られた顆粒を乾燥し、ＪＩＳ２４メッシュの篩にて篩過した。それによって得られた整粒品の内３５４．０ｇにステアリン酸マグネシウム６．０ｇを加え、ポリエチレン製の袋にて混合した。次いで、この混合物を、ロータリー式打錠機（菊水製作所製：ＶＥＬＡ５型）を用いて７００ｋｇｆの打圧で打錠して１錠重量１２０．０ｍｇの素錠（円形２段Ｒ錠、直径７．０ｍｍ、厚さ３．３ｍｍ）を得た。 [Comparative Example C2]
Lactose hydrate 944.0 g and low-substituted hydroxypropylcellulose 60.0 g were put into a fluidized bed granulator (manufactured by Paulek: MP-01 type) and mixed, and 65.0 g of hypromellose was purified water. Fluidized bed granulation was performed by spraying and drying a liquid in which 111.0 g of esomeprazole magnesium hydrate was suspended in a liquid dissolved in 1120.0 g. The granules thus obtained were dried and sieved through a JIS 24 mesh sieve. 6.0 g of magnesium stearate was added to 354.0 g of the granulated product thus obtained and mixed in a polyethylene bag. Subsequently, this mixture was tableted with a punching pressure of 700 kgf using a rotary tableting machine (manufactured by Kikusui Seisakusho: VELA type 5), and an uncoated tablet having a tablet weight of 120.0 mg (circular two-stage R tablet, diameter 7. 0 mm, thickness 3.3 mm).

実施例３〜８及び比較例Ｃ１、Ｃ２で得られた各々の錠剤の処方は下記の表４に一覧して示す。   The formulations of each tablet obtained in Examples 3-8 and Comparative Examples C1, C2 are listed in Table 4 below.

Figure 2018095632
Figure 2018095632

〔試験例３〕過酷な保存条件下での原薬の安定性試験
実施例３〜６及び比較例Ｃ１、Ｃ１、Ｂ２の各錠剤、エソメプラゾールマグネシウム水和物を含有する或る製剤処方のカプセル剤を、温度６０℃の密封条件下又は温度６０℃相対湿度７５％の開放条件下で７日間又は１４日間保存した後に、総類縁体の量を測定した。其の測定は高速液体クロマトグラフィー法（定量方法は面積百分率法を使用した。）によって行った。上記の測定結果は下記の表５に示す。 [Test Example 3] Stability test of drug substance under harsh storage conditions Each tablet of Examples 3 to 6 and Comparative Examples C1, C1 and B2, and a pharmaceutical formulation containing esomeprazole magnesium hydrate After the capsules were stored for 7 or 14 days under sealed conditions at a temperature of 60 ° C. or open conditions at a temperature of 60 ° C. and a relative humidity of 75%, the amount of total analogues was measured. The measurement was performed by the high performance liquid chromatography method (quantitative method used area percentage method). The measurement results are shown in Table 5 below.

Figure 2018095632
Figure 2018095632

〔試験例４〕
実施例７、８で得られた各々の錠剤について、第１６改正日本薬局方・一般試験法の溶出試験法により試験開始５分後、１０分後、１５分後、３０分後、４５分後、６０分後、９０分後及び１２０分後のエソメプラゾールマグネシウム水和物の溶出率を求め、結果（ｎ＝３）を下記の表６に示した。
使用した装置：溶出試験機／ＮＴＲ‐６１００型（富山産業製）
紫外線吸光光度計／ＵＶ‐１６００型（島津製作所製）
測定条件：試験液：日局第２液（ｐＨ６．８）
試験液量：９００ｍＬ
パドル回転数：５０ｒｐｍ
液温：３７℃
測定波長（エソメプラゾール）：２９２．５ｎｍ [Test Example 4]
For each of the tablets obtained in Examples 7 and 8, 5 minutes, 10 minutes, 15 minutes, 30 minutes, and 45 minutes after the start of the test according to the dissolution test method of the 16th revised Japanese Pharmacopoeia / General Test Method The elution rate of esomeprazole magnesium hydrate after 60 minutes, 90 minutes and 120 minutes was determined, and the results (n = 3) are shown in Table 6 below.
Equipment used: Dissolution tester / NTR-6100 (Toyama Sangyo)
Ultraviolet absorptiometer / UV-1600 type (manufactured by Shimadzu Corporation)
Measurement conditions: Test liquid: JP 2nd liquid (pH 6.8)
Test solution volume: 900 mL
Paddle rotation speed: 50 rpm
Liquid temperature: 37 ° C
Measurement wavelength (esomeprazole): 292.5 nm

Figure 2018095632
Figure 2018095632

表５において、乳糖水和物を含まない実施例３〜６の錠剤は、乳糖水和物を含む比較例Ｃ１、Ｃ２の錠剤に比べて保存後の総類縁体の発生量が低いことが示され、特に開放条件下（吸湿しやすい条件下）でより顕著に低いことが示された。よって本発明の錠剤は、結合水を含む添加物（水和物等）をより低量で含む方が保存時におけるエソメプラゾールの化学的な安定性において好ましいことが示唆される。   In Table 5, it is shown that the tablets of Examples 3 to 6 containing no lactose hydrate have a lower generation amount of the total analog after storage than the tablets of Comparative Examples C1 and C2 containing lactose hydrate. In particular, it was shown to be significantly lower under open conditions (under conditions that easily absorb moisture). Therefore, it is suggested that the tablet of the present invention preferably contains a lower amount of an additive (such as a hydrate) containing bound water in terms of chemical stability of esomeprazole during storage.

表６において、実施例７、８の錠剤は同程度の溶出性を示すことがみられた。よって本発明のフィルムコーティング錠剤は原薬の溶出性も良好であることが確認された。   In Table 6, it was found that the tablets of Examples 7 and 8 showed the same level of dissolution. Therefore, it was confirmed that the film-coated tablet of the present invention has good dissolution of the drug substance.

本発明によれば、過酷な保存条件下での安定性に優れた、エソメプラゾールの塩を含有する錠剤を製造（望ましくは工業的に簡便な方法で）することが可能となる。よって、其の高品質な錠剤を医療現場に提供することも併せて可能となる。   ADVANTAGE OF THE INVENTION According to this invention, it becomes possible to manufacture the tablet containing the salt of esomeprazole excellent in stability under severe storage conditions (preferably by an industrially simple method). Therefore, it is also possible to provide such high-quality tablets to the medical site.

Claims (12)

エソメプラゾールマグネシウム水和物並びに吸湿性が低い添加剤が素錠の全重量に対して８０．０重量％以上含有された、吸湿量が抑制された素錠。 A plain tablet with suppressed moisture absorption, containing 80.0% by weight or more of esomeprazole magnesium hydrate and a low hygroscopic additive based on the total weight of the plain tablet. 吸湿性が低い添加剤が水和物ではない、請求項１に記載の素錠。 The uncoated tablet according to claim 1, wherein the additive having low hygroscopicity is not a hydrate. エソメプラゾールマグネシウム水和物を素錠の全重量に対して６．０〜５０．０重量％含有する、請求項１又は２に記載の素錠。 The uncoated tablet according to claim 1 or 2, comprising 6.0 to 50.0% by weight of esomeprazole magnesium hydrate based on the total weight of the uncoated tablet. 吸湿性が低い賦形剤を含み、前記の賦形剤がＤ-マンニトール、キシリトール、白糖、スクロース及びトレハロースから選択されるものである、請求項１〜３のいずれかに記載の素錠。 The uncoated tablet according to any one of claims 1 to 3, comprising an excipient having low hygroscopicity, wherein the excipient is selected from D-mannitol, xylitol, sucrose, sucrose and trehalose. 吸湿性が低い賦形剤を含み、前記の賦形剤が素錠の全重量に対して５０．０重量％以上含有される、請求項１〜４のいずれかに記載の素錠。 The uncoated tablet according to any one of claims 1 to 4, comprising an excipient having low hygroscopicity, wherein the excipient is contained in an amount of 50.0% by weight or more based on the total weight of the uncoated tablet. エソメプラゾールの金属塩を含む造粒物を含有する、請求項１〜５のいずれかに記載の素錠。 The plain tablet in any one of Claims 1-5 containing the granulated material containing the metal salt of esomeprazole. 吸湿性が高い添加剤が素錠の全重量に対して２．０〜１０．０重量％含有される、請求項１〜６のいずれかに記載の素錠。 The plain tablet according to any one of claims 1 to 6, wherein an additive having high hygroscopicity is contained in an amount of 2.0 to 10.0% by weight based on the total weight of the plain tablet. 吸湿性が高い添加剤がトウモロコシデンプン、バレイショデンプン、コムギデンプン、コメデンプン、デンプングリコール酸ナトリウム、ポビドン、クロスポビドン、カルメロース、カルメロースカルシウム、低置換度ヒドロキシプロピルセルロース、ヒドロキシプロピルスターチ、クロスカルメロースナトリウムから選択されるものである、請求項７に記載の素錠。 Highly hygroscopic additives are corn starch, potato starch, wheat starch, rice starch, sodium starch glycolate, povidone, crospovidone, carmellose, carmellose calcium, low-substituted hydroxypropylcellulose, hydroxypropyl starch, croscarmellose sodium The uncoated tablet according to claim 7, which is selected from the following. 吸湿性が高い添加剤が崩壊剤であり、前記の崩壊剤が低置換度ヒドロキシプロピルセルロースである、請求項７に記載の素錠。 The uncoated tablet according to claim 7, wherein the additive having high hygroscopicity is a disintegrant, and the disintegrant is a low-substituted hydroxypropylcellulose. 塩基性の添加剤を含有しない、請求項１〜９のいずれかに記載の素錠。 The plain tablet in any one of Claims 1-9 which does not contain a basic additive. 請求項１〜１０のいずれかに記載の素錠がフィルムコーティング層で覆われた錠剤。 The tablet with which the uncoated tablet in any one of Claims 1-10 was covered with the film coating layer. エソメプラゾールマグネシウム水和物、１〜２種類の賦形剤、及び１〜２種類の崩壊剤を混合し、次いで其の混合物に１〜２種類の結合剤を含む造粒液を噴霧・乾燥して造粒物を製造し、続いて其の造粒物を１〜２種類の滑沢剤と混合した後に圧縮成形する、請求項１〜１０のいずれかに記載の素錠を製造する方法。
Esomeprazole magnesium hydrate, 1 to 2 types of excipients, and 1 to 2 types of disintegrant are mixed, and then the granulation liquid containing 1 to 2 types of binder is sprayed and dried in the mixture. The granulated product is produced, and then the granulated product is mixed with one or two kinds of lubricants and then compression-molded, The method for producing an uncoated tablet according to any one of claims 1 to 10 .
JP2017073369A 2016-12-15 2017-04-03 Tablets containing esomeprazole salts with improved chemical stability Active JP6336651B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2017/045018 WO2018110683A1 (en) 2016-12-15 2017-12-15 Tablet comprising an esomeprazole salt having improved chemical stability

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016243790 2016-12-15
JP2016243790 2016-12-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018088631A Division JP2018115217A (en) 2016-12-15 2018-05-02 Tablet containing the esomeprazole salt having improved chemical stability

Publications (2)

Publication Number Publication Date
JP6336651B1 JP6336651B1 (en) 2018-06-06
JP2018095632A true JP2018095632A (en) 2018-06-21

Family

ID=62487229

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017073369A Active JP6336651B1 (en) 2016-12-15 2017-04-03 Tablets containing esomeprazole salts with improved chemical stability
JP2018088631A Pending JP2018115217A (en) 2016-12-15 2018-05-02 Tablet containing the esomeprazole salt having improved chemical stability

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018088631A Pending JP2018115217A (en) 2016-12-15 2018-05-02 Tablet containing the esomeprazole salt having improved chemical stability

Country Status (2)

Country Link
JP (2) JP6336651B1 (en)
WO (1) WO2018110683A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006036774A (en) * 2004-07-26 2006-02-09 Astrazeneca Ab Medicinal preparation and its production method
JP2007524646A (en) * 2003-07-17 2007-08-30 ドクター レディズ ラボラトリーズ， インコーポレイテッド Pharmaceutical composition having a swellable coating
JP2008519070A (en) * 2004-11-04 2008-06-05 アストラゼネカ・アクチエボラーグ Novel modified release tablet formulations for proton pump inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007524646A (en) * 2003-07-17 2007-08-30 ドクター レディズ ラボラトリーズ， インコーポレイテッド Pharmaceutical composition having a swellable coating
JP2006036774A (en) * 2004-07-26 2006-02-09 Astrazeneca Ab Medicinal preparation and its production method
JP2008519070A (en) * 2004-11-04 2008-06-05 アストラゼネカ・アクチエボラーグ Novel modified release tablet formulations for proton pump inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
佐川良寿, 医薬品製剤技術 −粉砕・混合・造粒、乾燥・打錠・表面改質の実際−, JPN6018000872, 2002, pages 102 - 207, ISSN: 0003759457 *

Also Published As

Publication number Publication date
WO2018110683A1 (en) 2018-06-21
JP2018115217A (en) 2018-07-26
JP6336651B1 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
EP2691083B1 (en) Pharmaceutical composition of sitagliptin
SI23290A (en) New forms of ivabradine hydrochloride
TWI708603B (en) Pharmaceutical composition containing arylalkylamine compound
JP7212484B2 (en) METHOD FOR MANUFACTURING COMPRESSION-FORMED PREPARATION IN WHICH ACID RESISTANCE IS IMPROVED IN ENTERIC-COATED GRANULES
JP6007169B2 (en) Method for producing solid preparation containing aripiprazole anhydride
KR20190045286A (en) Pharmaceutical compositions comprising rosuvastatin and ezetimibe and methods for their preparation
JP2017048174A (en) Orally disintegrable tablet containing chemically stable coated particles containing drug substance
JP6366794B2 (en) Orally disintegrating tablets with improved chemical stability and dosage
JP2017222645A (en) Compression-molded tablet with improved acid resistance of enteric coated granules
JP2020121776A (en) Desiccant package of esomeprazole preparation
JP7066351B2 (en) Levodopa-containing miniaturized tablets with good sustained release
JP6336651B1 (en) Tablets containing esomeprazole salts with improved chemical stability
JP2019156723A (en) Permeation/swollen type in oral cavity collapse tablet using vehicle excellent in compression mold ability
WO2016114017A1 (en) Film-coated tablets containing olmesartan medoxomil
WO2020111089A1 (en) Pharmaceutical composition
JP6420508B2 (en) Formulation containing memantine hydrochloride with improved chemical stability
RU2642934C2 (en) Capsule composition
JP2020176107A (en) Coated tablet containing hygroscopic component
WO2015069203A1 (en) Capsule comprising rupatadine fumarate and montelukast sodium
JP2018172363A (en) Method for improving leachability of salt of medicine contained in enteric composition
JP2018172361A (en) Solid preparation containing duloxetine, having improved light stability
JP2011173796A (en) Mosapride citrate preparation
JP5827428B1 (en) Telmisartan-containing tablets
CA2973944C (en) Solid composition of pyrrole carboxamide
JP2019081753A (en) Enteric-coated preparation having improved leachability of duloxetine hydrochloride

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20180213

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180427

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180502

R150 Certificate of patent or registration of utility model

Ref document number: 6336651

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250